The Glucagon-like peptide-1 (GLP1) drugs are set to be the star performers for insulin drug makers across the globe as the menace of diabetes and obesity is in line to rise exponentially in the years to come. GLP1 drugs are medications which have traditionally been used to treat type 2…Read More
Novo Nordisks Diverse Obesity Drug Portfolio Holds Promise To Maintain Leadership John C Dawber
